Objectif The goal of this project is to provide a new antigen delivery system for vaccination purpose. We want to develop a vaccine platform based on pseudo-viral particles (VLP), able to enhance antigen immunogenicity and allow for screening multiple antigens independently or simultaneously. A chimeric influenza-VLP platform will be construct, where hemagglutinin (HA) protein will be modified to accommodate exogenous peptides containing B- and/or T- cell epitopes, thus allowing foreign antigen incorporation. The first objective is to select the best chimeric influenza-VLP construction to increase immunogenicity of vectorized antigens. The second objective is to provide a robust and scalable production process and a well-characterized chimeric influenza-VLP platform. The third objective is to validate our vaccination strategy by assaying its efficacy with malaria antigens to immunize against parasite infection and/or blood-stage development of the disease. The strength of this project and its high likelihood of success are based on a synergistic collaboration between three internationally recognized laboratories that would bring their complementary expertise to reach the ultimate goal of the project: delivering a new malaria vaccine-candidate. This will be supported by a complete characterization of the production process and of the final product for transfer to industrial manufacturing. The laboratory VirPath of Pr. Lina, will bring its expertise on influenza virus and vaccine production. Laboratory of Dr. Kamen NRC-Montréal developed for 2-3 years an influenza-VLP production technology based on HEK293 cells. We will transfer and exploit this know-how to select the best production process for chimeric influenza-VLPs and further optimize it. Choice of malaria target antigens and immunology tests on mouse models will be performed by the Malaria Immunology Laboratory of Dr. Rénia in Singapore, bringing its expertise and know-how of malaria immunopathology and vaccines. Champ scientifique medical and health scienceshealth sciencesinfectious diseasesmalarianatural sciencesbiological sciencesmicrobiologyvirologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) FP7-PEOPLE-2013-IIF - Marie Curie Action: "International Incoming Fellowships" Appel à propositions FP7-PEOPLE-2013-IIF Voir d’autres projets de cet appel Régime de financement MC-IIF - International Incoming Fellowships (IIF) Coordinateur UNIVERSITE LYON 1 CLAUDE BERNARD Contribution de l’UE € 194 046,60 Adresse BOULEVARD DU 11 NOVEMBRE 1918 NUM43 69622 Villeurbanne Cedex France Voir sur la carte Région Auvergne-Rhône-Alpes Rhône-Alpes Rhône Type d’activité Higher or Secondary Education Establishments Contact administratif Javier Olaiz (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
